Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
IGF-1 DES (DES) is a muscle peptide, at the research chemical stage in the published literature. Truncated IGF-1 missing first 3 amino acids. More potent than regular IGF-1 due to reduced binding protein affinity.
Truncated IGF-1 missing first 3 amino acids. More potent than regular IGF-1 due to reduced binding protein affinity.
| Research Status | Research chemical |
|---|---|
| Half-Life | 20-30 minutes |
| Administration | Intramuscular (site-specific) |
| Doses Reported in Published Studies | 50-150 mcg (site-specific) |
Binds IGF-1 receptor with greatly reduced binding protein affinity for enhanced bioactivity.
Truncated IGF-1 missing first 3 amino acids. More potent than regular IGF-1 due to reduced binding protein affinity.
Binds IGF-1 receptor with greatly reduced binding protein affinity for enhanced bioactivity.
IGF-1 DES is at the following stage in the published literature: Research chemical. All information is for research and educational purposes only.
Reported half-life: 20-30 minutes.
Reported administration route in the literature: Intramuscular (site-specific). This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.